INVO Bioscience Alpha and Beta Analysis
| INVODelisted Stock | USD 0.84 0.03 3.45% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as INVO Bioscience. It also helps investors analyze the systematic and unsystematic risks associated with investing in INVO Bioscience over a specified time horizon. Remember, high INVO Bioscience's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to INVO Bioscience's market risk premium analysis include:
Beta (2.92) | Alpha 0.74 | Risk 13.18 | Sharpe Ratio 0.0561 | Expected Return 0.74 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
INVO |
INVO Bioscience Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. INVO Bioscience market risk premium is the additional return an investor will receive from holding INVO Bioscience long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in INVO Bioscience. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate INVO Bioscience's performance over market.| α | 0.74 | β | -2.92 |
INVO Bioscience Fundamentals Vs Peers
Comparing INVO Bioscience's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze INVO Bioscience's direct or indirect competition across all of the common fundamentals between INVO Bioscience and the related equities. This way, we can detect undervalued stocks with similar characteristics as INVO Bioscience or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of INVO Bioscience's fundamental indicators could also be used in its relative valuation, which is a method of valuing INVO Bioscience by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare INVO Bioscience to competition |
| Fundamentals | INVO Bioscience | Peer Average |
| Return On Equity | -143.59 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Profit Margin | (1.23) % | (1.27) % |
| Operating Margin | (1.04) % | (5.51) % |
| Current Valuation | 15.19 M | 16.62 B |
| Shares Outstanding | 3.91 M | 571.82 M |
| Shares Owned By Insiders | 0.60 % | 10.09 % |
INVO Bioscience Opportunities
INVO Bioscience Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Disposition of tradable shares by Andrea Goren of INVO Bioscience subject to Rule 16b-3 | 09/05/2024 |
2 | INVO Bioscience and NAYA Biosciences Close Merger,Combined Company to Operate as NAYA Biosciences | 10/14/2024 |
3 | INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences | 10/21/2024 |
About INVO Bioscience Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including INVO or other delisted stocks. Alpha measures the amount that position in INVO Bioscience has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
INVO Bioscience Upcoming Company Events
As portrayed in its financial statements, the presentation of INVO Bioscience's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, INVO Bioscience's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of INVO Bioscience's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of INVO Bioscience. Please utilize our Beneish M Score to check the likelihood of INVO Bioscience's management manipulating its earnings.
| 15th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with INVO Bioscience
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in INVO Stock
If you are still planning to invest in INVO Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the INVO Bioscience's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |